Reports for the Oncology industry in Global

Oncology

Oncology

View Report: Research and Experts Market Report: Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis

Immuno-Oncology Strategic Insight - Multi-Indication And Market Size Analysis

Global
Market Report
2016-05-01
Report 05IC-GDHC057POA has a star rating of 3.8 out of 5
GlobalData estimates that the total IO market will be worth approximately $14 billion in 2019, rising to $34 billion by 2024 in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). The main drivers of this growth will come from immune checkpoint...
$10,995.00

View Report: Research and Experts Market Report: PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Renal Cell Carcinoma - Global Drug Forecast and Market Analysis to 2023

Global
Market Report
2016-04-21
Report 05IC-GDHC88PIDR has a star rating of 3.7 out of 5
Renal cell carcinoma (RCC) is among the 10 most frequently occurring cancers in Western countries. The RCC market is currently dominated by anti-angiogenic agents and tyrosine kinase inhibitors (TKIs) in particular, but it will experience dramatic changes...
$10,995.00

View Report: Research and Experts Market Report: PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Non-Small Cell Lung Cancer (NSCLC) - Global Drug Forecast and Market Analysis to 2025

Global
Market Report
2016-11-03
Report 05IC-GDHC134PIDR has a star rating of 4.4 out of 5
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the...
$10,995.00

View Report: Research and Experts Market Report: PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Negative/HR+ and Triple Negative Breast Cancer - Global Drug Forecast and Market Analysis to 2025

Global
Market Report
2016-12-14
Report 05IC-GDHC139PIDR has a star rating of 4.4 out of 5
Human epidermal growth factor receptor type 2 (HER2-) breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. HER2-negative breast cancer can be subdivided into hormone receptor-positive (HER2-/HR+),...
$10,995.00

View Report: Research and Experts Market Report: PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025

Global
Market Report
2017-01-05
Report 05IC-GDHC141PIDR has a star rating of 4.5 out of 5
The colorectal cancer (CRC) market, considering the sales of both branded treatments and generic chemotherapy, is expected to experience a moderate growth between 2015 and 2025. The main drivers of growth will be the expected increased number of diagnosed...
$10,995.00

View Report: Research and Experts Market Report: OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Bladder Cancer - Opportunity Analysis and Forecasts to 2025

Global
Market Report
2017-04-05
Report 05IC-GDHC067POA has a star rating of 4.2 out of 5
The bladder cancer market in the seven major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, and Japan) has remained largely unchanged in the past 10-20 years. However, significant expansion is expected starting in 2016, with the introducti...
$10,995.00

View Report: Research and Experts Market Report: OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

OpportunityAnalyzer: Ovarian Cancer - Opportunity Analysis and Forecasts to 2025

Global
Market Report
2017-05-01
Report 05IC-GDHC066POA has a star rating of 4.2 out of 5
Ovarian cancer is the fifth most common malignancy in women and is the leading cause of death amongst gynecological cancers. Due to the nonspecific nature of disease symptoms, the majority of ovarian cancer patients are diagnosed with advanced-stage disea...
$10,995.00

View Report: Research and Experts Market Report: OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026

OpportunityAnalyzer: Acute Myeloid Leukemia - Opportunity Analysis and Forecasts to 2026

Global
Market Report
2017-07-01
Report 05IC-GDHC074POA has a star rating of 4.4 out of 5
Acute myeloid leukemia (AML) is a rapidly progressing blood cancer with a poor overall prognosis. AML is relatively rare, and predominantly affects older adults. Although a number of acquired genetic and molecular abnormalities have been implicated in...
$10,995.00

View Report: Research and Experts Market Report: PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025

PharmaPoint: HER2-Positive Breast Cancer - Global Drug Forecast and Market Analysis to 2025

Global
Market Report
2017-06-24
Report 05IC-GDHC151PIDR has a star rating of 4.5 out of 5
HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. Today, HER2-positive breast cancer patients are living longer with their disease, thanks to established disease management strategies...
$10,995.00

View Report: Research and Experts Market Report: PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

PharmaPoint: Melanoma - Global Drug Forecast and Market Analysis to 2026

Global
Market Report
2017-09-29
Report 05IC-GDHC159PIDR has a star rating of 4.4 out of 5
Melanoma is the deadliest and most aggressive form of skin cancer. Melanoma is rare compared with other major cancer indications, but the incident cases are increasing because of the aging population and changes in lifestyle that result in more ultraviole...
$10,995.00

Page created and rendered - Cache updated [8.1341281s]